U.S. Pharmacogenomics Market, By Technology Type, By Application, By End User

U.S. Pharmacogenomics Market is estimated to be valued at USD 5,803.3 Mn in 2026 and is expected to reach USD 13,930.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.3% from 2026 to 2033.

Pharmacogenomics is a key branch of precision medicine that study the effect of genetic differences on a person's response to a drug, allowing the clinician to make better decisions regarding treatment, dosage, efficacy and safety. The U.S. market is gaining importance as healthcare providers move away from one-size-fits-all prescribing to targeted, patient-specific therapies.

The area includes applications in oncology, psychiatry, cardiology and infectious diseases and is supported by advances in next generation sequencing (NGS), bioinformatics and genomic databases. The incorporation of genetic information into clinical decision-making is increasing, which increases the utility of pharmacogenomics in modern healthcare and clinical pharmacy practice.

Market Dynamics

U.S. pharmacogenomics market is primarily driven by rising burden of adverse drug reactions, advances in next-generation sequencing (NGS) and the increasing federal support for precision medicine programs such as the NIH All of Us Research Program. Moreover, physician awareness and integration of pharmacogenomic tools into electronic health records (EHRs) are further driving clinical adoption.

However, the growth of market is limited by factors such as inconsistent reimbursement policies, lack of clinician proficiency, complex interpretation of genomic data, regulatory uncertainties, and genetic data privacy concerns. Nevertheless, there are abundant growth prospects due to factors such as increasing incidence of chronic diseases such as cancer, cardiovascular diseases and mental health disorders. The increasing availability of direct-to-consumer (DTC) genetic testing and telehealth services are improving patient access, and collaborations between pharmaceutical companies, diagnostic providers and academic institutions are accelerating the development of pharmacogenomic biomarkers and companion diagnostics.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. pharmacogenomics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Myriad Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Abbott Laboratories, and Eurofins Scientific SE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. pharmacogenomics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. pharmacogenomics market

Market Segmentation

• Technology Type Insights (Revenue, USD Mn, 2021 - 2033)
• DNA Sequencing
• Polymerase Chain Reaction
• Microarray
• Others
• Application Insights (Revenue, USD Mn, 2021 - 2033)
• Therapeutic Applications
• Drug Discovery
• End User Insights (Revenue, USD Mn, 2021 - 2033)
• Pharmaceutical and Biotechnology company
• Diagnostic Laboratories
• Academic and Research Institute
• Others
• Key Players Insights
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Hoffmann-La Roche Ltd
• QIAGEN N.V.
• Myriad Genetics, Inc.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories
• Eurofins Scientific SE